Merck Q4 Earnings Preview: Keytruda And Gardasil In Focus

Merck (NYSE: MRK) is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad. ThaMerck (NYSE: MRK) is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad. ThaRead MoreStocks,US Markets,InvestingStocks Feed